Related Experiment Video
Updated: Jan 13, 2026
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Enhancing Tuberculosis Diagnosis and Treatment Monitoring: Evaluating Ki67 and HLA-DR Biomarkers Via Point-of-Care
Mohammad Ilyas1, Ajay Singh1, Prasheelkumar Premnarayan Gupta2
1Department of Anaesthesia, Bundelkhand Medical College, Sagar, Madhya Pradesh, India.
Introduction:
Timely diagnosis and monitoring of tuberculosis (TB) remain critical challenges, especially in resource-limited settings. This study aimed to evaluate the diagnostic and treatment-monitoring utility of Ki67 and HLA-DR biomarkers in TB and to compare their quantification using flow cytometry and ELISA in whole blood samples.
Methods:
A total of 60 participants were enrolled, including 40 newly diagnosed TB patients and 20 healthy controls. Whole blood samples were analyzed at baseline, 2 months, and 6 months. Ki67 and HLA-DR expression were measured using both flow cytometry and ELISA. Statistical comparisons and agreement between methods were assessed using Pearson correlation and Bland-Altman analysis.
Results:
Both Ki67 and HLA-DR levels were significantly higher in TB patients compared with controls (P < 0.001). Biomarker levels declined progressively with treatment. ELISA values showed strong correlation with flow cytometry (r > 0.85), and Bland-Altman analysis demonstrated acceptable agreement with minimal bias.
Conclusion:
Ki67 and HLA-DR are promising biomarkers for TB diagnosis and treatment monitoring. ELISA provides a reliable, cost-effective alternative to flow cytometry, supporting its use in decentralized, point-of-care settings.
